GYRE
NASDAQ
US
Gyre Therapeutics, Inc. - Common Stock
$7,12
▼ $-0,11
(-1,52%)
Vol. 64K
8
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$641.7M
P/E
96,5
ROE
8,2%
Margine
6,2%
D/E
0,00
Beta
2,49
52W
$6–$14
Consenso Wall Street
9 analisti · Apr 20263
Acquisto forte
5
Compra
1
Mantieni
0
Vendi
0
Vendita forte
88,9%
Rating Compra
Grafico dei Prezzi
Titoli simili
BBOT
BridgeBio Oncology Therapeutics Inc
P/E 212,3
$1.0B
REPL
Replimune Group Inc
$762.5M
DSGN
Design Therapeutics Inc
$534.3M
PURR
Hyperliquid Strategies Inc
ALLO
Allogene Therapeutics Inc
$307.9M
PRME
Prime Medicine Inc
$626.4M
OCGN
Ocugen Inc
$421.6M
MDXG
MiMedx Group Inc
P/E 24,6
$1.0B
IRWD
Ironwood Pharmaceuticals Inc
P/E 19,2
$548.2M
Utili
Tasso di battuta: 25,0%
Prossimo report
Mag 07, 2026
Stima EPS: $-0,07
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,07 | — | — |
| Dic 2025 | $0,06 | $0,05 | $-0,01 |
| Set 2025 | $0,03 | $0,08 | +$0,05 |
| Giu 2025 | $0,03 | $0,02 | $-0,01 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $27.9M | $22.1M | $26.8M | $30.6M | $37.2M |
| Utile netto | — | -$99K | $2.7M | $442K | $3.6M | -$1.7M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 5.8% | 5.8% | 5.8% | 5.8% | 8.2% | 8.2% |
| P/E (TTM) | 155.47 | 166.17 | 167.59 | 169.01 | 110.80 | 96.48 |
| Net Margin | 1.6% | 4.1% | 4.1% | 4.1% | 6.2% | 6.2% |
| Gross Margin | 95.7% | 95.9% | 95.9% | 95.9% | 95.5% | 95.5% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.40 | 5.40 | 5.40 | 5.40 | 6.19 | 6.19 |
Rapporti chiave
ROA (TTM)
4,7%
P/S (TTM)
5,98
P/B
17,9
EPS (TTM)
$0,06
CF/Share
$-18,23
Crescita ricavi 3A
+143,3%
52W High
$14,42
52W Low
$6,11
$6,11
Intervallo 52 settimane
$14,42
Salute finanziaria
Flusso di cassa libero
-$5.8M
Debito netto
-$36.1M
Liquidità
$37.1M
Debito totale
$939K
Aggiornato al Dic 31, 2025
Як GYRE виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка GYRE vs аналоги Biotechnology
P/E
96,5
▲
414%
sopra
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
6,0
▼
53%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
17,9
▲
626%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість GYRE vs аналоги Biotechnology
ROE
8,2%
▲
112%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
6,2%
▲
102%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
95,5%
▲
21%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
4,7%
▲
110%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя GYRE vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
6,2
▲
40%
sopra
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
2,5
▲
157%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів GYRE
GYRE
Mediana peer
Industria
GYRE прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
GYRE vs аналоги: ключові метрики
Principali azionisti
Top 5: 2,8%Vanguard Group Inc
1,24%
$8.1M
Blackrock Inc.
0,74%
$4.9M
Geode Capital Management, L…
0,44%
$2.9M
State Street Corporation
0,21%
$1.4M
Charles Schwab Investment M…
0,17%
$1.1M
Aggiornato al Dic 31, 2025
Dividendi
$921,23
/ anno
Gen 13, 2023
$3,6000
Set 21, 2022
$21,4500
Ago 20, 2015
$896,1750
Ultime notizie
Nessuna notizia correlata ancora